Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Merck
Johnson and Johnson
AstraZeneca
Medtronic

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PAROMOMYCIN SULFATE

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Paromomycin Sulfate

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000771 ↗ A Double-Blind, Placebo-Controlled Trial of Paromomycin for Treatment of Cryptosporidiosis in Patients With Advanced HIV Disease and CD4 Counts Under 150 Cells/mm3 Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 1969-12-31 To determine the effectiveness of oral paromomycin sulfate for 21 days compared to placebo in the treatment of cryptosporidiosis in patients with HIV infection. To evaluate the safety of oral paromomycin at two different doses. To explore whether paromomycin administered over a longer period provides additional benefit. In previous studies, patients with cryptosporidiosis demonstrated dramatic improvement with paromomycin therapy.
NCT00001128 ↗ Treatment of Chronic Cryptosporidiosis in AIDS Patients Terminated Genetics Institute N/A 1969-12-31 The purpose of this study is to see if it is safe and effective to add interleukin-12 (IL-12) to the standard drug combination (paromomycin plus azithromycin) used to treat cryptosporidiosis in AIDS patients. Doctors would like to find out if the combination of IL-12, paromomycin, and azithromycin is more effective than paromomycin and azithromycin alone. Cryptosporidiosis is a type of opportunistic (AIDS-related) infection seen in HIV-positive patients as their immune systems weaken. It is caused by a parasite that invades the intestinal tract, and it can cause watery diarrhea, stomach cramps, an upset stomach, or a fever. Antibiotics (paromomycin and azithromycin) are usually used to treat cryptosporidiosis. In this study, doctors will look at the effectiveness of using IL-12. IL-12 is a type of protein naturally produced by certain types of cells of the immune system and is believed to be important for immune function. Doctors hope that IL-12 can help boost the immune system in fighting cryptosporidiosis.
NCT00001128 ↗ Treatment of Chronic Cryptosporidiosis in AIDS Patients Terminated National Institute of Allergy and Infectious Diseases (NIAID) N/A 1969-12-31 The purpose of this study is to see if it is safe and effective to add interleukin-12 (IL-12) to the standard drug combination (paromomycin plus azithromycin) used to treat cryptosporidiosis in AIDS patients. Doctors would like to find out if the combination of IL-12, paromomycin, and azithromycin is more effective than paromomycin and azithromycin alone. Cryptosporidiosis is a type of opportunistic (AIDS-related) infection seen in HIV-positive patients as their immune systems weaken. It is caused by a parasite that invades the intestinal tract, and it can cause watery diarrhea, stomach cramps, an upset stomach, or a fever. Antibiotics (paromomycin and azithromycin) are usually used to treat cryptosporidiosis. In this study, doctors will look at the effectiveness of using IL-12. IL-12 is a type of protein naturally produced by certain types of cells of the immune system and is believed to be important for immune function. Doctors hope that IL-12 can help boost the immune system in fighting cryptosporidiosis.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Paromomycin Sulfate

Condition Name

Condition Name for Paromomycin Sulfate
Intervention Trials
HIV Infections 2
Cryptosporidiosis 2
Leishmania Braziliensis Complex 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Paromomycin Sulfate
Intervention Trials
Leishmaniasis 3
HIV Infections 2
Cryptosporidiosis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Paromomycin Sulfate

Trials by Country

Trials by Country for Paromomycin Sulfate
Location Trials
United States 8
Bolivia 2
Sudan 2
Ethiopia 2
Kenya 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Paromomycin Sulfate
Location Trials
Texas 1
Ohio 1
New York 1
Missouri 1
Indiana 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Paromomycin Sulfate

Clinical Trial Phase

Clinical Trial Phase for Paromomycin Sulfate
Clinical Trial Phase Trials
Phase 3 1
Phase 2/Phase 3 1
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Paromomycin Sulfate
Clinical Trial Phase Trials
Completed 4
Terminated 1
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Paromomycin Sulfate

Sponsor Name

Sponsor Name for Paromomycin Sulfate
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 2
KU Leuven 1
Fundacion Nacional de Dermatologia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Paromomycin Sulfate
Sponsor Trials
Other 12
NIH 2
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Boehringer Ingelheim
Baxter
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.